Heartflow (HTFL) Gains from Investment Securities (2024 - 2025)
Heartflow (HTFL) posted Gains from Investment Securities of $9.3 million for Q4 2025, down 71.04% on a QoQ basis from $32.1 million in Q3 2025, and down 21.85% year-over-year from $11.9 million in Q4 2024.
Powered by 
Analysis
Heartflow (HTFL) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Heartflow has reported Gains from Investment Securities for 2 years, with the latest figure at $9.3 million in Q4 2025.
- On a quarterly basis, Gains from Investment Securities fell 21.85% year-over-year to $9.3 million in Q4 2025; TTM through Dec 2025 was $54.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $43.9 million, up 167.68% from the prior year.
- Gains from Investment Securities was $9.3 million for Q4 2025 at Heartflow, down from $32.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $32.1 million in Q3 2025, with the low at $585000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn |
| 10 | Prenetics Global | 357.49 Mn | 298.35 Mn | 30.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 9.30 Mn |
| Sep 30, 2025 | 32.12 Mn |
| Jun 30, 2025 | 863,000.00 |
| Dec 31, 2024 | 11.90 Mn |
| Sep 30, 2024 | 585,000.00 |
| Jun 30, 2024 | 3.91 Mn |